L ike the proverbial donkey that follows the carrot, tumor cells follow chemical attractants. Unlike the donkey, however, the tumor cells even make their own carrots, according to a report by Melody Swartz, Jacqueline Shields, Mark Fleury (École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland), and colleagues.
The group was interested in how tumor cells migrate to lymphatic vessels-the fi rst step in malignancy for most carcinomas. Migrating tumor cells express receptors for attractants that lymphatics normally produce to lure immune cells. Shields et al. now show that tumor cells don't need to rely on lymphatics to make the attractants they follow; they can produce the chemicals themselves.
A tumor cell would make no progress, however, if its secreted attractants were all around it. The group therefore predicted that the fl ow of tissue fl uids toward draining lymphatics concentrates the attractants downstream, ensuring that they always dangle alluringly in front of the tumor cell. Computer modeling of this flowinduced migration supported their prediction.
The authors then mimicked the fl uid dynamics and 3D structure of tumor tissue in culture. They found that blocking the attractant receptors on tumor cells prevented the cells from moving in the direction of the fl ow and prevented the reorganization of actin fi laments to the leading edge that is necessary for migration. The amount of attractants secreted by different tumor cells correlated with the strength of their self-mobilization and with their metastatic potential in vivo.
It's not yet clear how this new paradigm of autonomous signal-following activity will be applicable to cancer therapy, although the results suggest that blocking a tumor's secreted chemokines may help prevent its spread. Swartz also envisages one far-out surgical possibility: the replacement of a tumor with a kind of sponge to reverse the direction of fl ow in the tissue and chemoattractively mop-up remaining metastatic cells from the tumor's locality. The movement defects that characterize PD are caused by the death of dopaminergic neurons in a part of the brain called the substantia nigra pars compacta (SNc). SNc neurons have a pacemaking ability that ensures the regular release of small pulses of dopamine needed to maintain brain function.
Unlike other dopaminergic neurons, those in the SNc depend on calcium channels for pacemaking activity. According to Surmeier, however, mice that lack these calcium channels have no noticeable motor control defi cits. His group now shows that the pacemaking activity of these mutant SNc neurons is unaffected.
SNc neurons in the mutant mice carried on pacemaking by instead relying on sodium channels. Sodium channels were normally responsible for pacemaking only in young mice. As the neurons aged, sodium channels took over the pacemaking duties. Neurons from the mice lacking calcium channels thus continued to use the juvenile pacemaking strategy.
The group wondered whether they might revert wild-type adult SNc neurons to a similar juvenile state by simply blocking the calcium channels. Treating SNc neurons with a known calcium channel inhibitor, called isradipine, initially stopped pacemaking activity. After several hours of treatment, however, the pacemaking activity returned, now resembling that of juvenile neurons.
Evidence suggests that rising calcium levels inside SNc neurons might cause cell death in PD. The team found that isradipine reduced the loss of SNc neurons and prevented the development of motor deficits in a mouse model of PD.
Isradipine is a member of a class of drugs called dihydropyridines that are used to treat hypertension and stroke. Retrospective analysis of patient treatment data suggests that dihydropyridines reduce the incidence of PD. The fact the drug is approved for human use means that its effi cacy in preventing the progression of PD could be tested immediately. 
